Paul Hudson, Sanofi CEO (Eric Piermont/AFP via Getty Images)
August 17, 2022 06:21 AM EDTUpdated August 19, 04:07 AM
R&D

Up­dat­ed: Hit by an­oth­er PhI­II flop, Sanofi culls breast can­cer drug — sound­ing alarm for the class

Amber Tong

John Carroll

Editor & Founder

Sanofi is of­fi­cial­ly giv­ing up on its oral SERD.

The French drug­mak­er put out word Wednes­day morn­ing that it will

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

TRENDING NOW

Deputy FDA chief mulls shak­ing up PDU­FA reau­tho­riza­tion struc­ture

Up­dat­ed: No­vo Nordisk CEO to step down amid stock de­cline, time­line for suc­ces­sor un­known

Low­er at­ten­dance at cell and gene ther­a­py con­fer­ence mir­rors chal­lenged in­dus­try

The in­side sto­ry of the six-month sprint to cre­ate the first cus­tom CRISPR ther­a­py for one in­fant’s rare dis­ease

No­vo Nordisk’s glob­al obe­si­ty leader is mov­ing on; Flag­ship biotech gets CEO from Schol­ar Rock

FDA pos­es ef­fi­ca­cy, safe­ty ques­tions over four can­cer drugs ahead of two-day ad­comm

A service from the Financial Times